PF-Atlas › Clinical Trials › NCT02875366

A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis , Homozygous for the F508del-CFTR Mutation

LUM/IVA · Phase 4

Registry ID
NCT02875366
Phase
Phase 4
Status
Completed
Drug / intervention
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2016-09
Enrollment
70
Locations
12

About this trial

This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation. This study is designed to evaluate the effect of LUM/IVA on exercise tolerance in subjects with CF, homozygous for the F508del-CFTR mutation.

View NCT02875366 on ClinicalTrials.gov →

Explore related

All LUM/IVA trialsAll IPF trials

Related trials

LUM/IVA — NCT02797132LUM/IVA — NCT03125395LUM/IVA — NCT03061331
Medical disclaimer. This page summarizes public trial data for NCT02875366 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.